EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Folate‐Associated Gene Expression in Primary Tumors Is Associated With Tumor Response and Progression‐Free Survival of Patients With Metastatic Colorectal Cancer Undergoing 5‐ FU /Leucovorin‐Based Combination Chemotherapy

Elisabeth Odin, Göran Carlsson, Pushpa Saksena, Anders Edsjö, Alessandro Di Cara, Roger Tell, Bengt Gustavsson, Yvonne Wettergren iD

Cancer Medicine · 2025

DOI: 10.1002/cam4.70895 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Elisabeth Odin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Folic Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Isofol Medical AB, King Gustav V Jubilee Foundation for Cancer Research, The Swedish state under the LUA/ALF agreement.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

5‐Fluorouracil (5‐ FU ) and the Folate Leucovorin ( LV ) form the chemotherapy backbone for metastatic colorectal cancer ( mCRC ). Tumoral expression of specific folate‐associated genes is associated with the risk of recurrence in stage III CRC following adjuvant 5‐ FU / LV ( FLV )‐based combination chemotherapy according to the Nordic bolus regimen. The aim was to evaluate whether expression of folate‐associated genes in Pre‐therapeutic tumor samples is associated with outcomes of patients with mCRC undergoing palliative FLV ‐based combination chemotherapy. Patients and Methods Patients treated with FLV ( n = 113), FLV + oxaliplatin (FLOX, n = 102), or FLV + irinotecan (FLIRI, n = 75) were included. ABCC3 , RFC‐1, PCFT , MFT , MTHFD2 , and TYMS expression was determined by qPCR and related to tumor response and 3‐year progression‐free survival (PFS). Analyses were conducted on the entire cohort and on subgroups (group 1: stage I–III; group 2: stage IV, at primary surgery). Multivariate Cox proportional hazard models were applied to assess associations between covariates and PFS.

Results

Low TYMS and high MFT expression in group 1, and high ABCC3 expression in group 2 correlated with better PFS (HR 1.37 (1.04–1.82), HR 0.49 (0.30–0.80), and HR 0.74 (0.60–0.93)), respectively. In addition, high MFT expression was associated with better PFS of patients treated with FLIRI (HR 0.47 (0.27–0.81), p = 0.007) whereas high expression of ABCC3 was associated with better PFS of patients treated with FLOX (HR 0.46 (0.23–0.92), p = 0.029).

Conclusion

While pretherapeutic tumoral expression of specific folate‐associated genes may not serve as a universal predictive marker for FLV‐based treatment, it might predict response and outcomes in patients receiving FLOX or FLIRI. Evaluating the impact of gene expression in primary tumors should consider subgrouping of patients by disease stage at diagnosis as well as the applied chemotherapy regimen. Prospective clinical studies on patients with mCRC are warranted to validate these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsFolic AcidHumansFemaleMaleLeucovorinFluorouracilMiddle AgedAgedAdultProgression-Free SurvivalGene Expression Regulation, NeoplasticIrinotecanBiomarkers, TumorOxaliplatin

Substanzen

LeucovorinFluorouracilFolic AcidIrinotecanBiomarkers, TumorOxaliplatin

Autor:innen und Institutionen

  • Department of Surgery, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Department of Surgery, Sahlgrenska University Hospital, Region Västra Götaland, Gothenburg, Sweden.
  • Department of Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden.
  • Department of Clinical Genetics, Pathology, and Molecular Diagnostics, Office for Medical Services, Region Skåne, Lund, Sweden.
  • Division of Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
  • Lonza, Biologics R&D, Basel, Switzerland.

ORCID-Profile: Yvonne Wettergren

Förderung

  • Isofol Medical AB
  • King Gustav V Jubilee Foundation for Cancer Research
  • The Swedish state under the LUA/ALF agreement
  • IngaBritt and Arne Lundberg Foundation
  • Cancerfonden

Zitieren

APA

Odin, E., Carlsson, G., Saksena, P., Edsjö, A., Di Cara, A., Tell, R., Gustavsson, B., & Wettergren, Y. (2025). Folate‐Associated Gene Expression in Primary Tumors Is Associated With Tumor Response and Progression‐Free Survival of Patients With Metastatic Colorectal Cancer Undergoing 5‐ FU /Leucovorin‐Based Combination Chemotherapy. Cancer Medicine. https://doi.org/10.1002/cam4.70895

Vancouver

Odin E, Carlsson G, Saksena P, Edsjö A, Di Cara A, Tell R, et al. Folate‐Associated Gene Expression in Primary Tumors Is Associated With Tumor Response and Progression‐Free Survival of Patients With Metastatic Colorectal Cancer Undergoing 5‐ FU /Leucovorin‐Based Combination Chemotherapy. Cancer Medicine. 2025. doi:10.1002/cam4.70895

BibTeX
@article{Odin2025,
  author = {Odin, Elisabeth and Carlsson, Göran and Saksena, Pushpa and Edsjö, Anders and Di Cara, Alessandro and Tell, Roger and Gustavsson, Bengt and Wettergren, Yvonne},
  title = {Folate‐Associated Gene Expression in Primary Tumors Is Associated With Tumor Response and Progression‐Free Survival of Patients With Metastatic Colorectal Cancer Undergoing 5‐ FU /Leucovorin‐Based Combination Chemotherapy},
  journal = {Cancer Medicine},
  year = {2025},
  doi = {10.1002/cam4.70895}
}
Kostenlos starten →